Department of Gastrointestinal Surgery, Jinhua Guangfu Hospital, Jinhua, China.
Int J Exp Pathol. 2023 Oct;104(5):226-236. doi: 10.1111/iep.12487. Epub 2023 Jun 23.
Human gastrointestinal tumours have been shown to contain massive numbers of tumour infiltrating regulatory T cells (Tregs), the presence of which are closely related to tumour immunity. This study was designed to develop new Treg-related prognostic biomarkers to monitor the prognosis of patients with gastric cancer (GC). Treg-related prognostic genes were screened from Treg-related differentially expressed genes in GC patients by using Cox regression analysis, based on which a prognostic model was constructed. Then, combined with RiskScore, survival curve, survival status assessment and ROC analysis, these genes were used to verify the accuracy of the model, whose independent prognostic ability was also evaluated. Six Treg-related prognostic genes (CHRDL1, APOC3, NPTX1, TREML4, MCEMP1, GH2) in GC were identified, and a 6-gene Treg-related prognostic model was constructed. Survival analysis revealed that patients had a higher survival rate in the low-risk group. Combining clinicopathological features, we performed univariate and multivariate regression analyses, with results establishing that the RiskScore was an independent prognostic factor. Predicted 1-, 3- and 5-year survival rates of GC patients had a good fit with the actual survival rates according to nomogram results. In addition patients in the low-risk group had higher tumour mutational burden (TMB) values. Gene Set Enrichment Analysis (GSEA) demonstrated that genes in the high-risk group were significantly enriched in pathways related to immune inflammation, tumour proliferation and migration. In general, we constructed a 6-gene Treg-associated GC prognostic model with good prediction accuracy, where RiskScore could act as an independent prognostic factor. This model is expected to provide a reference for clinicians to estimate the prognosis of GC patients.
人类胃肠道肿瘤中含有大量肿瘤浸润调节性 T 细胞(Treg),其存在与肿瘤免疫密切相关。本研究旨在开发新的 Treg 相关预后生物标志物,以监测胃癌(GC)患者的预后。通过 Cox 回归分析从 GC 患者的 Treg 相关差异表达基因中筛选 Treg 相关预后基因,在此基础上构建预后模型。然后,结合 RiskScore、生存曲线、生存状态评估和 ROC 分析,验证模型的准确性,评估其独立预后能力。鉴定出 GC 中 6 个与 Treg 相关的预后基因(CHRDL1、APOC3、NPTX1、TREML4、MCEMP1、GH2),构建了一个 6 个基因的 Treg 相关预后模型。生存分析显示,低危组患者的生存率更高。结合临床病理特征,进行单因素和多因素回归分析,结果表明 RiskScore 是一个独立的预后因素。根据列线图结果预测的 GC 患者 1、3 和 5 年生存率与实际生存率拟合良好。此外,低危组患者的肿瘤突变负荷(TMB)值更高。基因集富集分析(GSEA)表明,高危组基因在与免疫炎症、肿瘤增殖和迁移相关的途径中显著富集。总的来说,我们构建了一个具有良好预测准确性的 6 个基因 Treg 相关 GC 预后模型,其中 RiskScore 可以作为独立的预后因素。该模型有望为临床医生评估 GC 患者的预后提供参考。